Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Assessing the long-term persistence and vector shedding of lentiviral vectors post-administration

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Assessing the long-term persistence and vector shedding of lentiviral vectors post-administration

Lentiviral Vector Persistence and Shedding Studies

CELL & GENE | RNA | BIOLOGICS

    What is the primary analytical method for vector shedding studies?

    A: Quantitative PCR (qPCR) and droplet digital PCR (ddPCR) are the standard methods. These assays are designed to be highly sensitive and specific for detecting vector sequences in various biological matrices like blood, urine, saliva, and feces to assess the potential for vector transmission.

    Which regulatory guidelines govern these studies?

    A: Guidance from the FDA, specifically the “Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products,” provides the framework. These studies are a required component of the BLA/MAA submission for most integrating vectors.

    How long should a lentiviral persistence study be?

    A: The duration is product-specific and determined by the intended therapeutic effect and preliminary nonclinical data. Studies often extend for several months to over a year to capture the full profile of vector clearance, persistence in target tissues, and potential for long-term expression.

    What sample types are required for a comprehensive analysis?

    A: A typical study requires serial collection of blood (for plasma and PBMCs), excreta (urine, feces), and swabs (e.g., saliva, nasal). At terminal time points, a comprehensive set of tissues is collected to perform non-target tissue biodistribution analysis.

Assessing the long-term persistence and potential for shedding of lentiviral vectors (LVV) is a foundational component of any IND-enabling safety program. These studies provide quantitative data on vector biodistribution, clearance, and potential for transmission, directly informing the risk assessment for patients and healthcare providers. Franklin Biolabs executes these complex, long-term studies using validated qPCR and ddPCR assays under a GxP framework to generate regulatory-compliant data packages.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Characterizing In Vivo Vector Fate

Lentiviral vectors are designed for stable integration into the host genome to achieve durable therapeutic effects. This mechanism necessitates a thorough investigation of the vector’s behavior following administration. Regulators require robust data demonstrating where the vector distributes, how long it persists in both target and non-target tissues, and whether it is shed from the body in a form that could be transmissible.

A comprehensive study design includes:

  • Biodistribution: Quantifying vector copy numbers across a full range of tissues at multiple time points.

  • Persistence: Tracking the level of vector sequences in target tissues over the life of the study to confirm stable integration and expression.

  • Shedding: Monitoring for the presence of vector DNA in excreta and bodily fluids to evaluate safety and environmental risk.

<a href=”

The Importance of Understanding Integration Mechanisms

The long-term behavior of any gene therapy vector is directly linked to its physical state within the cell. Research into other vector systems, such as AAV, has revealed that mechanisms like vector genome integration can be responsible for durable, long-term expression even when episomal persistence is the primary expected pathway (PMID: 37932420).

This principle underscores the need for rigorous analysis of vectors like lentivirus, which are engineered specifically for integration. Understanding the stability of the integrated provirus and monitoring for any potential mobilization over time is a key scientific and regulatory objective. Our approach is to develop and validate highly sensitive molecular assays that can precisely quantify vector sequences, providing a clear picture of vector fate to support your program’s safety narrative.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Designing a Regulatory-Compliant Study

Executing a successful long-term persistence and shedding study requires meticulous planning and infrastructure. Within our >100,000 sq ft facility, we manage these complex protocols with strict adherence to animal welfare standards, as accredited by AAALAC and overseen by the USDA, fully incorporating the 3Rs principles.

By integrating these studies early, sponsors can de-risk their development programs. The data generated are integral to the overall safety assessment, contributing to a well-supported IND package. Franklin Biolabs has a 100% IND success rate for programs it has supported since 2019 (the Franklin Biolabs brand itself launched in 2024), with a typical program timeline from initiation to IND filing spanning 18-24 months.

” ]

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities